<DOC>
	<DOCNO>NCT01197300</DOCNO>
	<brief_summary>This 1-year open-label extension CZOL446H2337 design evaluate safety efficacy zoledronic acid twice yearly osteoporotic child treat glucocorticoid .</brief_summary>
	<brief_title>1 Year Open-label Extension CZOL446H2337 Safety Efficacy Trial Zoledronic Acid Twice Yearly Osteoporotic Children Treated With Glucocorticoids</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Key Inclusion criterion : Written inform consent studyrelated procedure . Group 1 : 1 . Children adolescent , male female , 619 year old , meet inclusion criterion entry Core study take least one dose study drug complete Visit 8 CZOL446H2337 Core study . 2 . Patient must enrol extension Visit 9 10 month Visit 5 ( month 6 ) Core study . 3 . Patients follow regimen calcium vitamin D intake require Core study diet supplementation . Group 2 : 1 . Children adolescent , male female , 5 17 year old meet inclusion criterion entry Core study enrol clinically significant back pain vertebral fracture preexist clinical care Investigator site treat type patient bisphosphonate . 2 . Confirmed diagnosis nonmalignant condition ( include limit rheumatic condition , inflammatory bowel disease , Duchenne muscular dystrophy , nephrotic syndrome ) , treat systemic glucocorticoid ( i.v . oral ) within 12 month precede enrollment study ( duration ) 3 . LSBMD Zscore 0.5 worse confirm central image vendor 4 . Evidence least 1 vertebral compression fracture ( least Genant Grade 1 vertebral compression radiographic sign vertebral compression ) confirm central reading OR At least one low OR 2 upper extremity longbone , lowtrauma , fracture occur sometime within 2 year precede enrollment study , confirm radiological report . ( *Low trauma fracture define fall stand height less ) . Key Exclusion criterion : 1 . Major protocol violation Core Study ( Group 1 ) . 2 . Prior use bisphosphonates ( Group 2 ) sodium fluoride ( dose osteoporosis dental hygiene ) . 3 . Hypocalcemia hypophosphatemia : value ( agematched ) normal range Visit 8 8A . 4 . Vitamin D deficiency ( serum 25hydroxy vitamin D concentration &lt; 20 ng/mL &lt; 50 nmol/L ) Visit 8 ( Group 1 ) Visit 8A ( Group 2 ) . 5 . Renal impairment define estimate glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73 m2 screen base Schwartz formula Visit 8 8 A ; serum creatinine normal range Visit 9 ( Group 1 ) increase Visit 8A Visit 9 great 0.5 mg/dL ( 44.2 Î¼mol/L ) Group 2 . 6 . Female patient child bear potential eligible pregnant/nonlactating . Females child bear potential must practice medically acceptable form birth control great 2 month prior screen visit consent pregnancy test study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Osteoporosis , child adolescent , zoledronic acid , chronic inflammation , Duchenne muscular dystrophy , glucocorticoid</keyword>
</DOC>